RESUMEN
Aspartate transaminase, a liver specific enzyme released into serum following acute liver injury, is used in experimental organ preservation studies as a measure of liver IR injury. Whether post-operative serum transaminases are a good indicator of IR injury and subsequent graft and patient survival in human liver transplantation remains controversial. A single centre prospectively collected liver transplant database was analysed for the period 1988-2012. All patients were followed up for 5 years or until graft failure. Transaminase levels on the 1st, 3rd and 7th post-operative days were correlated with the patient demographics, operative outcomes, post-operative complications and both graft and patient survival via a binary logistic regression analysis. Graft and patient survival at 3 months was 80.3% and 87.5%. AST levels on the 3rd (P = 0.005) and 7th (P = 0.001) post-operative days correlated with early graft loss. Patients were grouped by their AST level (day 3): <107iU, 107-1213iU, 1213-2744iU and >2744iU. The incidence of graft loss at 3 months was 10%, 12%. 27% and 59% and 1-year patient mortality was 12%, 14%, 27% and 62%. Day 3 AST levels correlate with patient and graft outcome post-liver transplantation and would be a suitable surrogate endpoint for clinical trials in liver transplantation.
Asunto(s)
Aspartato Aminotransferasas/sangre , Trasplante de Hígado/mortalidad , Adolescente , Adulto , Anciano , Niño , Ensayos Clínicos como Asunto , Femenino , Supervivencia de Injerto , Humanos , Londres/epidemiología , Masculino , Persona de Mediana Edad , Periodo Posoperatorio , Estudios Prospectivos , Adulto JovenRESUMEN
BACKGROUND & AIMS: Liver transplant (LT) patients might be overimmunosuppressed as recommendations for tacrolimus trough concentrations (TC) within 4-6 weeks after liver transplantation are set too high (10-15 ng/ml). Early tacrolimus exposure was evaluated in relation to acute rejection and long-term outcomes. METHODS: Four hundred and ninety-three consecutive LT patients receiving tacrolimus as primary immunosuppression (1995-2008) were analyzed. Acute rejection was diagnosed using protocol biopsies at day 6.1 ± 2.5. Median follow-up was 7.3 years (IQR 3.9-10.5). Early tacrolimus exposure (<15 days) was evaluated against moderate/severe acute rejection, chronic rejection, graft loss, chronic renal impairment and mortality using multiple logistic and Cox regression. RESULTS: Maintenance immunosuppression was tacrolimus monotherapy (48.1%), double therapy combination with antimetabolites or steroids (18%), or triple therapy combination with antimetabolites and steroids (33.9%). Histological grade of acute rejection was moderate in 157 cases (31.8%) and severe in 19 cases (3.9%). Tacrolimus TC>7 ng/ml on the day of protocol biopsy was associated with less moderate/severe rejection (23.8%) compared with<7 ng/ml (41.2%) (p = 0.004). Mean tacrolimus TC 7-10 ng/ml within 15 days after LT were associated with reduced risk of graft loss (RR = 0.46; p = 0.014) compared to TC 10-15 ng/ml. A peak TC>20 ng/ml within this period was independently related to higher mortality (RR = 1.67; p = 0.005), particularly due to cardiovascular events, infections and malignancy (RR = 2.15; p = 0.001). Early tacrolimus exposure did not influence chronic rejection (p = 0.58), or chronic renal impairment (p = 0.25). CONCLUSIONS: During the first 2 weeks after LT, tacrolimus TC between 7 and 10 ng/ml are safe in terms of acute rejection and are associated with longer graft survival.
Asunto(s)
Rechazo de Injerto/inmunología , Rechazo de Injerto/prevención & control , Inmunosupresores/uso terapéutico , Trasplante de Hígado/inmunología , Índice de Severidad de la Enfermedad , Tacrolimus/uso terapéutico , Adulto , Relación Dosis-Respuesta a Droga , Femenino , Estudios de Seguimiento , Hepatitis C/cirugía , Humanos , Estimación de Kaplan-Meier , Fallo Hepático Agudo/cirugía , Neoplasias Hepáticas/cirugía , Trasplante de Hígado/mortalidad , Modelos Logísticos , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Tasa de Supervivencia , Factores de Tiempo , Resultado del TratamientoRESUMEN
Roux-en-Y loop is considered the reconstruction method of choice in Orthotopic Liver Transplantation (OLT) for Primary Sclerosing Cholangitis (PSC). We have adopted an approach of duct-to-duct (D-D) reconstruction when recipient common bile duct is free of gross disease. Patients were divided into two groups: patients who underwent a Roux-en-Y choledochojejunostomy and patients who had a D-D anastomosis. Morbidity, mortality, disease recurrence and graft and patient survival were compared between the two groups and analyzed. Ninety-one patients had OLT for PSC. Sixty-three patients underwent a D-D biliary reconstruction, whereas 28 patients had a Roux-en-Y loop. Biliary leak complicated 8% from the D-D group, and 14% from the Roux-en-Y group (P = 0.08), whereas biliary strictures were identified in 10% vs. 7% patients from the D-D and Roux-en-Y group, respectively (P = 0.9). Actuarial 1, 3 and 10 year survival for D-D and Roux-en-Y group was (87%, 80% and 62%) and (82%, 73% and 73%), respectively (P = 0.7). The corresponding 1, 3 and 10 year graft survival was (72%, 58% and 42%) and (67%, 58% and 53%), respectively (P = 0.6). No difference was seen in disease recurrence rates. D-D biliary reconstruction in OLT for selected PSC patients remains our first option of reconstruction.
Asunto(s)
Conductos Biliares/cirugía , Procedimientos Quirúrgicos del Sistema Biliar , Colangitis Esclerosante/terapia , Trasplante de Hígado/métodos , Adulto , Anastomosis en-Y de Roux/efectos adversos , Bases de Datos Factuales , Femenino , Rechazo de Injerto , Supervivencia de Injerto , Humanos , Masculino , Persona de Mediana Edad , Recurrencia , Resultado del TratamientoRESUMEN
Acute cellular rejection remains an important source of morbidity after liver transplantation, particularly if rejection is moderate or severe, as this usually is treated. Currently liver biopsies are seldom performed, so diagnostic noninvasive markers would be useful. We evaluated 690 consecutive first liver transplant patients to assess whether peripheral eosinophilia could predict moderate-severe rejection and its course. A protocol biopsy was performed 6 ± 2.5 days after transplant. A second biopsy was taken 6.1 ± 2 days after the first in 487 patients to assess histological improvement. Liver function tests, peripheral eosinophil count and changes between first and second biopsy, were evaluated using logistic regression. Histological rejection was present in 532 patients (77.1%), with moderate (30.6%) and severe rejection (3.9%). Peripheral eosinophil count was strongly associated with moderate-severe rejection (OR = 2.15; P = 0.007), although the area under ROC curve (AUROC) was 0.58. On second biopsy, rejection improved in 119 (24.4%) patients. The delta in eosinophil count between the first and second biopsies was the only independent predictor of histological improvement (OR = 3.12; P = 0.001), irrespective of whether bolus steroids were used (OR = 2.77; P = 0.004); AUROC was 0.72. Peripheral eosinophilia is not sufficiently predictive of moderate-severe histological rejection. However the changes in eosinophil count over time can accurately predict the histological resolution of rejection.
Asunto(s)
Eosinófilos , Rechazo de Injerto/sangre , Rechazo de Injerto/etiología , Trasplante de Hígado/efectos adversos , Corticoesteroides/administración & dosificación , Biopsia , Eosinofilia/sangre , Eosinofilia/etiología , Femenino , Rechazo de Injerto/tratamiento farmacológico , Rechazo de Injerto/patología , Humanos , Leucemia Eosinofílica Aguda , Recuento de Leucocitos , Trasplante de Hígado/patología , Masculino , Valor Predictivo de las Pruebas , Pronóstico , Estudios Prospectivos , Factores de TiempoRESUMEN
Hepatic artery thrombosis (HAT) is a serious complication in patients undergoing orthotopic liver transplantation (OLT). It is associated with a high graft loss and mortality rate. In this study, possible risk factors associated with early HAT (occurring within the first postoperative month) were evaluated using univariable and multivariable analyses. Nine-hundred-and-fourteen consecutive OLTs in our institution were examined by univariable and multivariable analyses. Early HAT occurred in 43 patients (4.7%). Graft number, abnormal donor arterial anatomy, bench arterial reconstruction, aortic conduit use, multiple anastomoses, reperfusion time (interval between portal vein reperfusion and restoration of arterial flow) and the number of units of blood received intraoperatively were significantly associated with early HAT in the univariable analysis(P<0.1). These variables were included in a multivariable regression model which showed that bench arterial reconstruction was associated with a fourfold risk of early HAT(P<0.0001), whereas each additional 10min delay in reperfusion was associated with a 27% increase in the risk of early HAT (P<0.04). The main risk factors associated with early HAT are abnormal arterial anatomy in the graft requiring bench reconstruction and a delay in arterial reperfusion. Early recognition of these factors, strict surveillance protocols with arterial Doppler and selective anticoagulation for patients at risk need to be evaluated prospectively.
Asunto(s)
Arteria Hepática , Trasplante de Hígado/efectos adversos , Trombosis/etiología , Femenino , Arteria Hepática/cirugía , Humanos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Análisis de Regresión , Factores de Riesgo , Procedimientos Quirúrgicos Vasculares/efectos adversosRESUMEN
Aprotinin is an antifibrinolytic drug that reduces blood loss during orthotopic liver transplantation (OLT). Case reports have suggested that aprotinin may be associated with an increased risk of thromboembolic complications. Recent studies in cardiac surgery also have suggested a higher risk of renal failure and postoperative mortality. Despite these concerns, no large-scale safety assessment has been performed in OLT. In a retrospective observational study involving 1492 liver transplants, we studied the occurrence of postoperative thromboembolic or thrombotic events and mortality in patients who received aprotinin (n = 907) and patients who did not (n = 585). The overall incidence of hepatic artery thrombosis and central venous complications (pulmonary embolism or inferior vena cava thrombosis) was 3.2% and 0.9%, respectively. In propensity score-adjusted analyses (C-index = 0.79), aprotinin was not associated with an increased risk of hepatic artery thrombosis [odds ratio (OR) = 1.00, 95% confidence interval (CI) = 0.50-2.01, P = 0.86]. Although central venous complications were found more frequently in patients receiving aprotinin, the difference was not statistically significant (OR = 2.95, 95% CI = 0.54-16.23, P = 0.32). In addition, no significant differences were found in 1-year mortality (OR = 1.21, 95% CI = 0.86-1.71, P = 0.32). In conclusion, this study did not demonstrate an increased risk of thrombotic complications or mortality when aprotinin is used during OLT.
Asunto(s)
Aprotinina/farmacología , Trasplante de Hígado/métodos , Trombosis/etiología , Adulto , Femenino , Hemostáticos/farmacología , Arteria Hepática/patología , Humanos , Fallo Hepático/complicaciones , Fallo Hepático/terapia , Masculino , Persona de Mediana Edad , Oportunidad Relativa , Estudios Retrospectivos , Riesgo , Trombosis/complicaciones , Resultado del TratamientoRESUMEN
BACKGROUND: We sought to investigate the impact of different immunosuppressive regimens on human cytomegalovirus (HCMV) incidence and replication dynamics in a cohort of 256 patients after liver transplantation. METHODS: A time-updated approach was used to determine the risk of developing HCMV replication (>200 genomes/mL blood) within the first 100 days after liver transplantation according to the immunosuppressive regimen being received at specific time points. RESULTS: In patients receiving tacrolimus, the addition of prednisolone was associated with a significant increased risk of HCMV replication both at baseline (relative rate of infection [RRI]=4.34; P=0.0001) and in a time-updated analysis (RRI=4.68; P=0.0001). However, the addition of azathioprine substantially reduced the risk of HCMV replication to that observed with tacrolimus alone. As expected donor/recipient HCMV serostatus was also a risk factor for viraemia. Multivariable models showed that the tacrolimus plus prednisolone regimen and donor/recipient serostatus were independent risk factors for HCMV replication. Viral replication dynamics showed that the duration of HCMV viraemia, the peak viral load, and the growth rate of HCMV were greatest in patients receiving tacrolimus plus prednisolone although these differences did not reach statistical significance. CONCLUSIONS: The combination of prednisolone plus tacrolimus as baseline immunosuppression after liver transplantation is associated with a high risk of HCMV replication. This effect can be negated by the addition of azathioprine.
Asunto(s)
Azatioprina/farmacología , Infecciones por Citomegalovirus/virología , Citomegalovirus/efectos de los fármacos , Citomegalovirus/fisiología , Trasplante de Hígado , Prednisolona/farmacología , Replicación Viral/efectos de los fármacos , Adolescente , Adulto , Anciano , Femenino , Humanos , Inmunosupresores/farmacología , Masculino , Persona de Mediana EdadRESUMEN
BACKGROUND: Calcineurin inhibitors (CNIs) are the first-line immunosuppressive agents administered after liver transplantation, but they cause renal impairment. Two recent randomized trials report cellular rejection and liver graft loss when mycophenolate mofetil (MMF) monotherapy was used as a renal-sparing agent. Our experience with MMF in the same setting but with longer follow-up is described. METHODS: In 45 patients with serum creatinine more than 120 micromol/L or creatinine clearance less than 50 mL/min, 2 g MMF per day was administered (median 29 months, 1-49 months) either as monotherapy (with all other immunosuppression withdrawn in 1 month) in 16 patients (group I) or in combination with low-dose CNI (trough tacrolimus =5 ng/mL, cyclosporin A =50 ng/mL) in 29 patients (18 patients without [group II] and 11 patients with [group III] previous refractory rejection [rejection after two episodes of treated rejection]). RESULTS: In group I (median interval receiving MMF, 33 months), only one patient (6%) experienced cellular rejection, and serum creatinine normalized in five of eight patients long term. In group II (median follow-up 26.5 months), none of 18 experienced rejection, and serum creatinine normalized in 6 of 10 long term. In group III (median follow-up 34 months), 5 of 11 patients (45%) experienced further rejection, one was not steroid responsive, and serum creatinine normalized in four of eight patients long term. There was no graft loss or death as a result of rejection. CONCLUSIONS: Our cohort with prolonged follow-up showed significant improvement in renal function with both MMF monotherapy and in combination with low-dose CNI with minimal rejection (five of six steroid responsive) and no graft loss. MMF substitution is a therapeutic strategy that deserves more extensive use in liver transplantation.
Asunto(s)
Inhibidores de la Calcineurina , Inmunosupresores/uso terapéutico , Enfermedades Renales/tratamiento farmacológico , Trasplante de Hígado/efectos adversos , Ácido Micofenólico/uso terapéutico , Adulto , Anciano , Enfermedad Crónica , Creatinina/sangre , Femenino , Rechazo de Injerto , Humanos , Masculino , Persona de Mediana Edad , Ácido Micofenólico/análogos & derivadosRESUMEN
At present, the relation between alcoholic consumption and the development of hepatic injury is clearly defined. However, the influence of genetic factors, the existence of associated pathologies, and the concomitant use of other hepatotoxic agents should also be considered.During chronic drunkenness, great quantities of oxygen free radicals are produced, redox balance is disturbed, and the defensive capacity of natural antioxidants is exceeded. All these factors originate an "oxidative stress," that totally distorts the hepatocellular function. Llkewise, an increase in the acetaldehyde intracellular concentration modifies several cellular proteins, deteriorating even more the hepatic activity. The importance of the "neo-antigens" between cellular components and acetaldehyde is still undefined, as well as their role in the formation of the Mallory Bodies.On the other hand, the complex network of intercellular and intracellular communications that includes cytokines, adherence molecules and membrane receptors are essential elements to be considered in the alcoholic liver disease genesis. The endotoxin, the TNF-a, the IL-8, as well as the ROIs production seem to be the most important factors.With reference to Alcoholic Hepatitis, the development of an exaggerated inflammatory response with the existence of neutrophiles may be the main mechanism of hepatocellular injury (82, 167, 168.)The final diagnosis of Alcoholic Hepatitis is histological. This also enables to measure the injury severity and to determine the presence of fibrosis and/or cirrhosis, in which case prognosis is more uncertain.Should a history of exaggerated alcoholic ingestion exist, diagnosis could be clinically determined. There is a great variability of clinical symptoms, and some patients present chronic liver disease complications frequently. Those who develop severe liver insufficiency will present leukocytosis, icterus and fever. In these cases, mortality can be as high as 80 per cent. There is no relationship between the alteration of liver function tests and the injury severity.The usefulness of antioxidants in cirrhosis has been demonstrated in animal modeis and in some studies made in human voluntarles. However, their role as therapy within the context of Alcoholic Hepatitis has not been yet defined.In conclusion, several therapeutic approaches have been investigated and from all of them, only steroids have proven to be effective on patients properly selected. The discriminative function (DF) benefit has been confirmed in certain studies. Should a patient have a DIF of more than 93, he/she may receive corticosterold treatment. Contral ndicati ons are a bsol ute when the patientpresents infection, renal insufficiency or gastrointestinal bleeding.Once the patient has been compensated, ABSTINENCE is essential. Likewise, an appropriate nutritional support is an important part of the treatment.Where the possibility of Liver Transplant exists, this should be planned if there is a deterioration of the patient's general condition or if he/she compiles with the necessary criteria, since the survival rate in these cases is similar to those who received a transpiant due to other causes.
RESUMEN
Alcoholic hepatitis represents the most severe form of alcoholic liver disease Recent research points to an exaggerated inflammatory response, mediated by neutrophils,as the basic mechanism of liver damage. This entity has a distinctive clinical picture and a characteristic histopathology and a poor outcome.Recent investigation reveals a complex network of intracellular and intercellular communication signals involving hepatocytes, endothelial cells, monocytes, lymphocytes, neutrophils,Ito and Kupffer cells, leading to massive migration of neutrophils from blood to liver.When neutrophils reach the liver, multiple cytokines produced locally by endothelium, hepatocytes and Kupffer cells, up-regulate their function. Activation of neutrophils leads to increased production of oxygen radicals(mainly superoxide)and hydrogen peroxide production.To date there is general agreement that measurement of superoxide production by neutrophils is a reliable way of determining neutrophil function and its activation.Thirty one patients with acute alcoholic hepatitis, twenty with compensated alcoholic liver disease end seventeen controls were studied.Patients with alcoholic hepatitis and alcoholic liver disease were enrolled on admission to the hospital and if they had no features of infection, bleeding or renal failure.The neutrophil stimuli used were opsonized zymosan and fMLP.The production of superoxide was similar in the three groups when neutrophils were not stimulated.After stimulation with opsonized zymosan,there was an increase in the production of superoxide from patients with acute alcoholic hepatitis in comparison to those with alcoholic liver disease and controls. This increase was statistically significant when fMLP was the stimulant(p<0.05). This is a reliable technique that can be use in the evaluation of different therapeutic modalities in acute alcoholic hepatitis
RESUMEN
Anticoagulation may in the future become a therapeutic option for the prevention of liver fibrosis, such as due to recurrent hepatitis C virus infection after liver transplantation. Currently, there are other indications for anticoagulation after liver transplantation but no data regarding its safety. The objective of the study was to audit the safety of anticoagulation after liver transplantation. Liver transplant recipients receiving anticoagulation postoperatively were compared with a matched control group with respect to bleeding complications and postoperative course. Anticoagulation did not increase the risk of bleeding complications after liver transplantation. On the basis of safety, it appears feasible to use anticoagulation in trials to assess prevention of liver fibrosis.
Asunto(s)
Anticoagulantes/efectos adversos , Anticoagulantes/uso terapéutico , Hemorragia/inducido químicamente , Trasplante de Hígado/métodos , Adolescente , Adulto , Recolección de Datos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Femenino , Fibrosis/prevención & control , Humanos , Incidencia , Trasplante de Hígado/efectos adversos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Warfarina/efectos adversos , Warfarina/uso terapéutico , Adulto JovenRESUMEN
Liver transplantation (LT) is the only therapeutic option for end-stage primary sclerosing cholangitis (PSC), but PSC can recur (rPSC) in some patients after LT. The aim of our study was to evaluate the risk factors associated with rPSC. Between 1989 and 2004, 69 patients receiving transplantation for PSC (42 male, mean age 41.9 yr). Clinical and laboratory data, activity/extension and treatment of ulcerative colitis (UC), post-LT cytomegalovirus (CMV) infection, and immunosuppression were evaluated. Determination of rPSC was made by radiological and histological findings. Exclusion criteria were ABO blood group incompatibility, hepatic artery stenosis, and biliary strictures occurring in <3 months post-LT. A total of 48 (70%) patients had PSC and UC pre-LT. rPSC occurred in 7 of 53 (13.5%, 2 patients with de novo UC) who were alive 1 yr after LT and/or met inclusion/exclusion criteria: median 60 (4-120) months. No patient without post-LT UC had rPSC: 0 of 20 vs. 7 of 26 with post-LT UC (P = 0.027). The multivariate logistic regression analysis showed that maintenance steroids for UC (>3 months) post-LT was the only risk factor significantly associated with rPSC (P = 0.025). In conclusion, the presence of UC post-LT, and the need for maintenance steroids post-LT, which is an independent factor, are associated with rPSC. These findings could help elucidate a possible mechanism of PSC pathogenesis.
Asunto(s)
Colangitis Esclerosante/cirugía , Colitis Ulcerosa/complicaciones , Trasplante de Hígado , Adolescente , Adulto , Anciano , Colangiografía , Colangitis Esclerosante/diagnóstico por imagen , Colangitis Esclerosante/etiología , Colangitis Esclerosante/mortalidad , Colitis Ulcerosa/tratamiento farmacológico , Colitis Ulcerosa/epidemiología , Femenino , Estudios de Seguimiento , Humanos , Trasplante de Hígado/estadística & datos numéricos , Modelos Logísticos , Londres/epidemiología , Masculino , Persona de Mediana Edad , Recurrencia , Reoperación , Medición de Riesgo , Factores de Riesgo , Esteroides/efectos adversos , Factores de Tiempo , Resultado del TratamientoRESUMEN
Combined disparity of human leukocyte antigen (HLA)-DR and -DQ between mother and fetus is associated with less severe ulcerative colitis (UC) during pregnancy. We evaluated whether donor-recipient HLA disparity after liver transplantation (LT) affects UC in patients with primary sclerosing cholangitis (PSC). Sixty-nine consecutive patients with PSC underwent LT; all underwent colonoscopy before LT; 48 had UC before and 3 had de novo UC after LT. Clinical and laboratory data, activity and treatment of UC, post-LT cytomegalovirus infection, and disparity of HLA-A, -B, -DR, and -DQ for each donor-recipient pair were evaluated. Pre-LT quiescent UC was present in 26 patients. Post-LT UC activity was evaluated in 36 of 51 patients with UC who had not undergone pre-LT colectomy and who had >12 months' post-LT survival. Of these, 16 were stable, 17 had worsened, and 3 had de novo UC. Seven required colectomy (4 for dysplasia or cancer) after LT. Post-LT cytomegalovirus viremia was neither associated with worse UC activity (P = 0.58) nor de novo UC. Disparity with respect to HLA-A, -B, -DR, and -DQ was found in 58%, 27%, 44%, and 39% donor-recipient pairs, respectively. Post-LT UC course was similar with respect to single HLA disparity. However, disparity in none or only one HLA-DR or -DQ was significantly associated with worse activity compared with patients with disparity at both (65% vs. 0%, P = 0.009). Logistic regression found that the disparity for both -DR and -DQ was the only factor statistically significantly associated with post-LT UC activity. We conclude that disparity in both HLA-DR and -DQ between donor and recipient is associated with stable UC activity after LT.
Asunto(s)
Colangitis Esclerosante/cirugía , Colitis Ulcerosa/inmunología , Antígenos HLA-DQ/inmunología , Antígenos HLA-DR/inmunología , Trasplante de Hígado/inmunología , Complicaciones Posoperatorias/inmunología , Adolescente , Adulto , Anciano , Colangiocarcinoma/epidemiología , Femenino , Prueba de Histocompatibilidad , Humanos , Neoplasias Hepáticas/epidemiología , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Resultado del TratamientoRESUMEN
Predictive factors for intrahepatic cholestasis after orthotopic liver transplantation (OLT) have not yet been established. We sought to identify the incidence and risk factors associated with prolonged severe intrahepatic cholestasis (PSIC) after OLT. We assessed 428 consecutive patients undergoing their first OLT. PSIC was diagnosed if a serum bilirubin concentration was greater than 100 micromol/L and/or a 3-fold increase of alkaline phosphatase occurred within the first month after OLT and was sustained for at least 1 week in the absence of biliary complications. Multivariable logistic regression identified factors independently associated with PSIC. PSIC developed in 107 patients (25%). Independent risk factors by multivariable analysis were intraoperative transfusion of cryoprecipitate and platelets; nonidentical blood group status; suboptimal organ appearance; inpatient status before transplantation; and bacteraemia in the first month after transplantation. In contrast, acute liver failure, older age, and higher levels of serum sodium and serum potassium were all associated with a reduced likelihood of developing PSIC in the first month. There were 47 deaths in the PSIC group (44%) as opposed to 65 deaths in the non-PSIC group (20%) after OLT. A poor preoperative clinical status in conjunction with a suboptimal graft was associated with PSIC after OLT. Avoidance of suboptimal livers and ABO nonidentical grafts for young patients with poor synthetic function and for pretransplant inpatients may lessen this complication and reduce the associated early mortality.
Asunto(s)
Colestasis Intrahepática/epidemiología , Colestasis Intrahepática/fisiopatología , Trasplante de Hígado/efectos adversos , Enfermedad Aguda , Adolescente , Adulto , Anciano , Envejecimiento , Bacteriemia/etiología , Incompatibilidad de Grupos Sanguíneos , Niño , Colestasis Intrahepática/etiología , Enfermedad Crónica , Factor VIII/uso terapéutico , Femenino , Fibrinógeno/uso terapéutico , Humanos , Incidencia , Cuidados Intraoperatorios , Fallo Hepático/cirugía , Trasplante de Hígado/mortalidad , Masculino , Persona de Mediana Edad , Análisis Multivariante , Transfusión de Plaquetas , Potasio/sangre , Factores de Riesgo , Índice de Severidad de la Enfermedad , Sodio/sangre , Factores de TiempoRESUMEN
In HCV cirrhotic patients after liver transplantation, survival and recurrence of HCV appears to be worsening in recent years. Donor age has been suggested as a cause. However, it is not clear if early and/or late mortality is affected and whether donor age is a key factor, as opposed to changes in immunosuppression. The aim of this study was to assess impact of donor age and other factors with respect to the severity of HCV recurrence posttransplant. A consecutive series of 193 HCV cirrhotic patients were transplanted with cadaveric donors, median age 41.5 years (13-73) and median follow-up of 38 months (1-155). Donor age and other factors were examined in a univariate/multivariate model for early/late survival, as well as fibrosis (grade 4 or more, Ishak score) with regular biopsies, 370 in total, from 1 year onwards. Results of the study indicated that donor age influenced only short-term (3 months) survival, with no significant effect on survival after 3 months. Known HCC independently adversely affected survival, as did the absence of maintenance azathioprine. Severe fibrosis (stage > or = 4) in 51 patients was related to neither donor age nor year of transplantation, but it was independently associated with combined biochemical/histological hepatitis flare (OR 2.9, 95% CI 1.76-4.9) whereas maintenance steroids were protective (OR 0.4, 95% CI 0.23-0.83). In conclusion, in this cohort donor age did not influence late mortality in HCV transplanted cirrhotic patients or development of severe fibrosis, which was related to absence of maintenance steroids and a hepatitis flare. Maintenance azathioprine gave survival advantage.
Asunto(s)
Hepatitis C/mortalidad , Inmunosupresores/uso terapéutico , Trasplante de Hígado , Ácido Micofenólico/análogos & derivados , Adulto , Factores de Edad , Anciano , Azatioprina/uso terapéutico , Ciclosporina/administración & dosificación , Quimioterapia Combinada , Femenino , Glucocorticoides/uso terapéutico , Supervivencia de Injerto , Hepatitis C/cirugía , Humanos , Cirrosis Hepática/cirugía , Cirrosis Hepática/virología , Trasplante de Hígado/inmunología , Trasplante de Hígado/mortalidad , Masculino , Persona de Mediana Edad , Ácido Micofenólico/administración & dosificación , Prednisolona/administración & dosificación , Recurrencia , Tacrolimus/administración & dosificaciónRESUMEN
Late hepatic artery thrombosis (HAT) is a rare complication after orthotopic liver transplantation (OLT), conventionally described as occurring more than 30 days after surgery. Only a few reports document its course. In a consecutive series of 634 OLTs (704 grafts), 11 patients (1.7%) had late HAT, diagnosed a median of 6 months (range, 1.8 to 79 months) after OLT. Clinical variables were compared with those of 415 patients without HAT who had a complete database and follow-up, including cytomegalovirus (CMV) surveillance. At presentation, 11 patients had fever, 4 patients had jaundice. Hepatic abscesses were present in 6 patients (3 patients with biliary leak), 4 patients had biliary tree necrosis (2 patients with biliary leak), and 1 patient had no biliary complications. Five patients (45%) underwent accessory hepatic artery anastomosis versus 73 patients (17%) without HAT (P <.05). Five patients (45%) with late HAT had CMV infection versus 14% without HAT (P <.05). Two episodes of late HAT (11 and 79 months) occurred in patients who underwent re-OLT for early HAT (3.9%). Re-OLT was performed in 8 patients a median of 11 days (range, 3 to 37 days) after diagnosis (preceded by intravenous antibiotics and percutaneous drainage). The other 3 patients underwent partial hepatectomy (1 patient), external percutaneous drainage as unfit for surgery (1 patient), and antibiotic therapy only (1 patient). Death occurred in 4 patients who underwent re-OLT (50%) because of septicemia at 11, 23, and 60 days after re-OLT and 17 days after a third OLT. There was one late death (30 months) after partial hepatectomy (hepatitis C recurrence) and one death 6 months after long-term biliary drainage because of sepsis. The 5 survivors have good health with normal liver function test results at a median 52 months (range, 6 to 57 months). In conclusion, late HAT presents with fever caused by hepatic abscesses or biliary leak associated with biliary ischemia and necrosis. CMV infection and accessory hepatic artery anastomosis are risk factors for late HAT in our cohort. Early intervention followed by re-OLT can salvage patients.
Asunto(s)
Arteria Hepática , Trasplante de Hígado/mortalidad , Trombosis/diagnóstico , Trombosis/mortalidad , Adulto , Anciano , Femenino , Estudios de Seguimiento , Hepatectomía , Humanos , Inmunosupresores/uso terapéutico , Masculino , Persona de Mediana Edad , Complicaciones Posoperatorias/diagnóstico , Complicaciones Posoperatorias/mortalidad , Hemorragia Posoperatoria/diagnóstico , Hemorragia Posoperatoria/mortalidad , Reoperación , Factores de Riesgo , Sepsis/diagnóstico , Sepsis/mortalidad , Factores de Tiempo , Resultado del TratamientoRESUMEN
An optimum antimicrobial regimen for bacterial infection after orthotopic liver transplantation has not been identified. In this prospective 4 year study of patients undergoing liver transplantation, patients were randomized to receive either piperacillin-tazobactam (112 patient episodes) or ciprofloxacin plus amoxicillin (105 patient episodes) for empirical treatment of infective episodes in the first 3 months after transplant. Metronidazole was added to the ciprofloxacin-amoxicillin regimen where anaerobic infection was suspected. Patient groups were comparable with respect to clinical, biochemical and haematological parameters. At the 72 h primary efficacy end-point, the overall response rate for the intention-to-treat group was 74/112 (66.1%) for piperacillin-tazobactam and 63/105 (60.0%) for ciprofloxacin plus amoxicillin (P=0.399); the corresponding figures for the per-protocol (PP) group were 73/82 (89.0%) (piperacillin-tazobactam) and 61/80 (76.3%) (ciprofloxacin plus amoxicillin) (P=0.038). At the end-of-study assessment, 58.9% of episodes in the piperacillin-tazobactam group had a successful clinical outcome, compared with 50.5% in the ciprofloxacin plus amoxicillin group (P=0.222); the corresponding figures for the PP group were 83.5% (piperacillin-tazobactam) and 68.8% (ciprofloxacin plus amoxicillin) (P=0.038). Staphylococci and aerobic Gram-negative bacilli were the predominant pathogens in both groups. Bacteria resistant to the study drugs were encountered, including methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium and multiply-resistant Klebsiella spp. Empirical monotherapy with piperacillin-tazobactam is an effective treatment for infective episodes in liver transplant patients.
Asunto(s)
Amoxicilina/uso terapéutico , Antibacterianos/uso terapéutico , Infecciones Bacterianas/tratamiento farmacológico , Ciprofloxacina/uso terapéutico , Quimioterapia Combinada/uso terapéutico , Trasplante de Hígado , Ácido Penicilánico/uso terapéutico , Penicilinas/uso terapéutico , Piperacilina/uso terapéutico , Complicaciones Posoperatorias/tratamiento farmacológico , Adolescente , Adulto , Anciano , Amoxicilina/efectos adversos , Antibacterianos/efectos adversos , Infecciones Bacterianas/microbiología , Ciprofloxacina/efectos adversos , Método Doble Ciego , Quimioterapia Combinada/efectos adversos , Enterobacteriaceae/efectos de los fármacos , Femenino , Fiebre/etiología , Humanos , Masculino , Metronidazol/uso terapéutico , Persona de Mediana Edad , Ácido Penicilánico/efectos adversos , Ácido Penicilánico/análogos & derivados , Penicilinas/efectos adversos , Piperacilina/efectos adversos , Combinación Piperacilina y Tazobactam , Complicaciones Posoperatorias/microbiología , Estudios Prospectivos , Staphylococcus aureus/efectos de los fármacosRESUMEN
The liver in subacute hepatic failure may become enriched for hepatic progenitor cells. Liver tissue from such a patient was collagenase digested and, from the nonparenchymal cell fraction, epithelioid colonies were developed. Albumin and alpha-1-antitrypsin (AAT) were secreted for greater than 120 days from these colonies. Reverse transcription-polymerase chain reaction showed expression of markers of both hepatocyte and biliary epithelial phenotypes (cytokeratins 7, 18, and 19, albumin and AAT, hepatocyte growth factor receptor, transforming growth factor beta receptor type II, gamma-glutamyl transpeptidase, biliary glycoprotein). The cell cycle regulator p21 was also expressed. The POU domain transcription factor octamer-binding protein 4 was present in these cells, but not in RNA or cDNA prepared from adult human liver. These markers were maintained even after 165 days culture. Proliferating epithelial-like cells with combined hepatocyte- and biliary-epithelial-specific functional markers and a stem cell marker can be isolated from the nonparenchymal fraction of liver cells in subacute hepatic failure.
Asunto(s)
Células Epiteliales/patología , Fallo Hepático/patología , Hígado/citología , Células Madre/patología , Conductos Biliares Intrahepáticos/citología , Biomarcadores , Técnicas de Cultivo de Célula/métodos , Células Cultivadas , Células Epiteliales/metabolismo , Femenino , Hepatocitos/metabolismo , Hepatocitos/patología , Humanos , Hígado/patología , Regeneración Hepática , Persona de Mediana Edad , Fenotipo , Células Madre/metabolismoRESUMEN
Actualmente, la relación entre consumo de alcohol y el desarrollo de daño hepático está claramente definida. Sin embargo, también debe considerarse la influencia de los factores genéticos, la existencia de enfermedades asociadas y el uso concomitante de otros agentes hepatotóxicos. Durante el etilismo crónico se producen grandes cantidades de radicales libres de oxígeno, se altera el equilibrio redox y se sobrepasa la capacidad defensiva de los antioxidantes naturales. Todos estos factores originan "stres oxidativo", que distorciona completamente la función hepatocelular. Asismismo, el incremento en la concentración intracelular de acetaldehido, modifica diversas proteinas celulares, lo que deteriora aún más la actividad hepática. Está aún por definirse la importancia de los "neoantígenos", entre componentes celulares y el acetaldehido, así como su rol en la formación de los cuerpos de Mallory. por otro lado, la complicada red de comunicaciones inter e intracelulares que comprende a las citoquinas, a las moléculas de adherencia y a los receptores de membrana son elementos indispensables a considerar en la génesis de la hepatopatía alcohólica. La endotoxina, el TNF-a, la IL-8, así como la producción de ROIs son al parecer los factores más importantes. En relación a hepatitis alcohólica, el desarrollo de una respuesta inflamatoria exagerada y mediada por neutrófilos sería el mecanismo básico de injuria hepatocelular. El diagnóstico definitivo de hepatitis alcohólica es histológico. Este permite además, graduar la severidad del daño y determinar la presencia de fibrosis y/o cirrosis en cuyo caso el pronóstico es más sombrío. Clínicamente el diagnóstico puede plantearse teniendo el antecedente de ingesta exagerada de alcohol. Existe gran variabilidad en el cuadro clínico, y no es infrecuente que algunos pacientes presenten las complicaciones de la hepatopatía crónica. Los que desarrollan insuficiencia hepática severa, presentarán leucocitosis, ictericia y fiebre. En estos casos la mortalidad puede llegar hasta 80 por ciento. La alteración de las pruebas de función hepática no guardan relación con al severidad del daño. La utilidad de los antioxidantes en cirrosis ha sido demostrada en modelos animales y en algunos estudios en voluntarios humanos. Su rol como terapia en el contexto de hepatitis alcohólica, esta por ser definida...
Asunto(s)
Hepatitis Alcohólica/diagnóstico , Hepatitis Alcohólica/terapiaRESUMEN
La formación de una conexión extrapilórica no quirúrgica entre el antro gástrico y el bulbo duodenal está en investigación en los últimos veinte años. Expresiones tales como "píloro doble" "pseudopíloro", "úlcera en tunel", "diafragma pilórico" y "banda mucosa antral" probablemente describen la misma lesión. Reportamos 3 casos con evidencia radiológica y endoscópica.